company background image
ARTH logo

Arch Therapeutics OTCPK:ARTH Stock Report

Last Price

US$0.25

Market Cap

US$1.6m

7D

-20.0%

1Y

-68.7%

Updated

07 Nov, 2024

Data

Company Financials

Arch Therapeutics, Inc.

OTCPK:ARTH Stock Report

Market Cap: US$1.6m

ARTH Stock Overview

Operates as a biotechnology company in the United States.

ARTH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Arch Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Arch Therapeutics
Historical stock prices
Current Share PriceUS$0.25
52 Week HighUS$18.00
52 Week LowUS$0.17
Beta3.61
11 Month Change-21.75%
3 Month Change-59.61%
1 Year Change-68.70%
33 Year Change-98.92%
5 Year Change-99.20%
Change since IPO-99.77%

Recent News & Updates

Recent updates

Shareholder Returns

ARTHUS Medical EquipmentUS Market
7D-20.0%2.1%5.1%
1Y-68.7%31.2%37.7%

Return vs Industry: ARTH underperformed the US Medical Equipment industry which returned 29.2% over the past year.

Return vs Market: ARTH underperformed the US Market which returned 35.1% over the past year.

Price Volatility

Is ARTH's price volatile compared to industry and market?
ARTH volatility
ARTH Average Weekly Movement46.6%
Medical Equipment Industry Average Movement8.1%
Market Average Movement6.2%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.9%

Stable Share Price: ARTH's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ARTH's weekly volatility has increased from 41% to 47% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20068Terrence Norchiwww.archtherapeutics.com

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company’s flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds.

Arch Therapeutics, Inc. Fundamentals Summary

How do Arch Therapeutics's earnings and revenue compare to its market cap?
ARTH fundamental statistics
Market capUS$1.56m
Earnings (TTM)-US$12.99m
Revenue (TTM)US$148.16k

7.5x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARTH income statement (TTM)
RevenueUS$148.16k
Cost of RevenueUS$89.52k
Gross ProfitUS$58.64k
Other ExpensesUS$13.05m
Earnings-US$12.99m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.92
Gross Margin39.58%
Net Profit Margin-8,769.17%
Debt/Equity Ratio-74.7%

How did ARTH perform over the long term?

See historical performance and comparison